263567-38-0

Basic information

• Product Name: 4-BROMO-3,5-DIMETHOXYBENZOYL HYDRAZINE
• Synonyms: 4-BROMO-3,5-DIMETHOXYBENZOYL HYDRAZINE;4-bromo-3,5-dimethoxyBenzoic acid hydrazide;4-Bromo-3,5-dimethoxybenzohydrazide
• CAS NO: 263567-38-0
• Molecular Formula: C9H11BrN2O3
• Molecular Weight: 275.1
• Product Categories: Aromatic Hydrazides, Hydrazines, Hydrazones and Oximes
• Mol File: 263567-38-0.mol

Chemical Properties

• Appearance: /
• Density: 1.518±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 11.22±0.10(Predicted)
• CAS DataBase Reference: 4-BROMO-3,5-DIMETHOXYBENZOYL HYDRAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-3,5-DIMETHOXYBENZOYL HYDRAZINE(263567-38-0)
• EPA Substance Registry System: 4-BROMO-3,5-DIMETHOXYBENZOYL HYDRAZINE(263567-38-0)

Safety Data

• Hazardous Substances Data: 263567-38-0(Hazardous Substances Data)

Usage

General Description

4-Bromo-3,5-dimethoxybenzoyl hydrazine is a chemical compound with the molecular formula C9H10BrN3O3. It is a hydrazine derivative that contains a bromine atom and two methoxy groups attached to a benzoic acid core. 4-BROMO-3,5-DIMETHOXYBENZOYL HYDRAZINE has been used in the synthesis of various pharmaceuticals and may also have potential bioactive properties. Its precise applications and properties have not been extensively studied, but it is likely to be of interest in medicinal and organic chemistry research due to its structural features and potential for biological activity.

Upstream product

• 56518-42-4 4-bromo-3,5-dimethoxybenzoic acid 
• 26050-64-6 methyl 4-bromo-3,5-dimethoxybenzoate 

Downstream Products

• 444932-31-4 2-(3,5-dimethoxybenzoyl)-N-(naphthalen-1-yl)hydrazine-1-carboxamide 

Relevant articles and documents

Radiosynthesis and characterisation of a potent and selective GPR139 agonist radioligand

Compound 1 is a selective and potent agonist of the G protein-coupled receptor GPR139 (EC50 = 39 nM). In this study, we describe the synthesis, radiolabelling and in vitro evaluation of [3H]-1 for the characterisation of GPR139 and its spatial expression in the brain using autoradiography. Two different synthesis routes for the radiolabelling of 1 based on a reductive debromination strategy were investigated using deuterium (D2, g). The route based on reductive debromination of the bromonaphthyl precursor 5 proved superior over arylbromide 4 and was employed for the radiolabelling experiments. Reductive debromination of precursor 5 was accomplished using 3H2, Pd/C and triethylamine in DMF at ambient temperature to give target molecule [3H]-1 with a specific activity of 19.3 Ci mmol-1 and a radiochemical purity of ≥95%. By application of autoradiography and binding studies, it was not possible to discriminate [3H]-1 binding to wildtype mice brains from GPR139 knockout mice brains and total binding from non-specific binding in CHO-k1 cells stably expressing human GPR139 receptor. Based on these experiments we conclude that [3H]-1 is not a suitable radioligand for the characterisation of GPR139.